Initial Therapeutics is an ATP company that develops small-molecule medicines designed to prevent pathogenic protein synthesis. The company provides an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they are fully formed for medical needs.

Initial Therapeutics

Peiwen Yu

Director, Discovery Science

Jim Li

The Scientific Research Team at Initial Therapeutics is responsible for conducting advanced research to identify and develop small-molecule medicines aimed at preventing pathogenic protein synthesis. This involves employing a range of scientific techniques, including computational biology, to discover and validate targets, as well as to optimize drug candidates for therapeutic use.

Scientific Research Team

About

Team members